Skip to main content
Article thumbnail
Location of Repository

Markers of early disease and prognosis in COPD

By Morten Dahl and Børge G Nordestgaard


COPD is a complex disease with multiple pathological components, which we unfortunately tend to ignore when spirometry is used as the only method to evaluate the disorder. Additional measures are needed to allow a more complete and clinically relevant assessment of COPD. The earliest potential risk factors of disease in COPD are variations in the genetic background. Genetic variations are present from conception and can determine lifelong changes in enzyme activities and protein concentrations. In contrast, measurements in blood, sputum, exhaled breath, broncho-alveolar lavage, and lung biopsies may vary substantially over time. This review explores potential markers of early disease and prognosis in COPD by examining genetic markers in the α1-antitrypsin, cystic fibrosis transmembrane conductance regulator (CFTR), and MBL-2 genes, and by examining the biochemical markers fibrinogen and C-reactive protein (CRP), which correlate with degree of pulmonary inflammation during stable conditions of COPD. Chronic lung inflammation appears to contribute to the pathogenesis of COPD, and markers of this process have promising predictive value in COPD. To implement markers for COPD in clinical practice, besides those already established for the α1-antitrypsin gene, further research and validation studies are needed

Topics: Reviews
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1989). A book of tables with data from the fi rst examination (1976–78) and a fi ve year follow-up (1981–83). The Copenhagen City Heart Study Group. Scand J Soc Med Suppl.
  2. (1995). A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene.
  3. (2001). A pilot survey of cystic fi brosis clinical manifestations in CFTR mutation heterozygotes. Genet Test.
  4. A population-based study of morbidity and mortality in mannose-binding lectin defi ciency.
  5. Acute respiratory tract infections and mannose-binding lectin insuffi ciency during early childhood.
  6. (1994). Adenovirus-mediated cytokine gene transfer at tissue sites. Overexpression of IL-6 induces lymphocytic hyperplasia in the lung.
  7. (1994). Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway infl ammation and bronchial hyperreactivity.
  8. Airway hyperresponsiveness and airway obstruction in transgenic mice. Morphologic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung.
  9. Association between chronic obstructive pulmonary disease and systemic infl ammation: a systematic review and a meta-analysis.
  10. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema.
  11. (2003). Association studies for asthma and atopic diseases: a comprehensive review of the literature. Respir Res.
  12. (2005). Asthma and COPD in cystic fi brosis intron-8 5T carriers. A population-based study. Respir Res.
  13. (2007). C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med.
  14. CFTR and asthma in the French EGEA study.
  15. (2006). CFTR gene mutations and asthma in the Norwegian Environment and Childhood Asthma study. Respir Med.
  16. (2001). CFTR gene mutations–including three novel nucleotide substitutions – and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet.
  17. (2002). Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. Ann Intern Med.
  18. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis.
  19. (2003). Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol.
  20. (1998). Cystic fi brosis Delta F508 heterozygotes, smoking, and reproduction: studies of 9141 individuals from a general population sample.
  21. (1993). Cystic fi brosis transmembrane conductance regulator splice variants are not conserved and fail to produce chloride channels. Nat Genet.
  22. (1973). Cystic fi brosis: population genetics. Tex Rep Biol Med.
  23. DeltaF508 heterozygosity in cystic fi brosis and susceptibility to asthma.
  24. (2008). Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J.
  25. (2001). Elevated plasma fi brinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med.
  26. (1984). Epidemiology of chest pain and angina pectoris, with special reference to treatment needs. Acta Med Scand Suppl.
  27. (2008). Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J.
  28. Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fi brosis phenylalanine-508 deletion.
  29. Gender differences in the association between C-reactive protein, lung function impairment, and COPD.
  30. Genetic determinants of emphysema distribution in the national emphysema treatment trial.
  31. Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease.
  32. Genetics of chronic obstructive pulmonary disease.
  33. (1997). Geographic distribution and regional origin of 272 cystic fi brosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat.
  34. (2001). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med.
  35. (1995). Heterozygotes for the delta F508 cystic fi brosis allele are not protected against bronchial asthma. Nat Med.
  36. (2003). Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis.
  37. (1996). Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-defi cient mice infected with Candida albicans.
  38. (2000). Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fl uids of idiopathic nonspecifi c interstitial pneumonia. Am J Respir Crit Care Med.
  39. Infl ammatory markers in COPD.
  40. (2001). Interleukin-6 changes deformability of neutrophils and induces their sequestration in the lung. Am J Respir Crit Care Med.
  41. (1998). Interleukin-6 production in hemorrhagic shock is accompanied by neutrophil recruitment and lung injury.
  42. Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults.
  43. (2003). Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun.
  44. (1999). Missense mutations in the cystic fibrosis gene in adult patients with asthma. Hum Mutat.
  45. (2008). Molecular Biomarkers for quantitative and discrete COPD phenotypes.
  46. (2001). Molecular diagnosis of intermediate and severe alpha(1)-antitrypsin defi ciency: MZ individuals with chronic obstructive pulmonary disease may have lower lung function than MM individuals. Clin Chem.
  47. (2002). Molecular diagnosis of intermediate and severe alpha1-antitrypsin defi ciency by use of multiplex polymerase chain reaction.
  48. Molecular pathogenesis of emphysema.
  49. Outcomes and markers in the assessment of chronic obstructive pulmonary disease.
  50. (2008). Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J.
  51. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev.
  52. Polymers and infl ammation: disease mechanisms of the serpinopathies.
  53. Progress in chronic obstructive pulmonary disease genetics.
  54. (2002). Projections of global mortality and burden of disease from
  55. (1995). Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fi brosis. Nat Med.
  56. (2007). Protection against inhaled oxidants through scavenging of oxidized lipids by macrophage receptors
  57. (2008). Proteomics of human lung tissue identifi es surfactant protein a as a marker of chronic obstructive pulmonary disease. J Proteome Res.
  58. (1997). Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.
  59. (2005). Role of interleukin-6 in murine airway responses to ozone. Am J Physiol Lung Cell Mol Physiol.
  60. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease.
  61. Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical lung damage induced by smoking.
  62. Superoxide dismutase 3 polymorphism associated with reduced lung function in two large populations.
  63. (2008). The clinical utility of biomarkers in asthma and COPD. Curr Opin Pharmacol.
  64. (2001). The Copenhagen City Heart Study – Østerbroundersøgelsen. Tables with data from the third examination 1991–1994. Eur Heart J Suppl.
  65. The development of asthma in children infected with Chlamydia pneumoniae is dependent on the modifying effect of mannose-binding lectin.
  66. The effects of fl uticasone with or without salmeterol on systemic biomarkers of infl ammation in chronic obstructive pulmonary disease.
  67. The pathogenic consequences of a single mutated CFTR gene.
  68. (2005). The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J.
  69. (2003). The role of mannose-binding lectin in health and disease. Mol Immunol.
  70. The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.